Chemotherapy is an important treatment for advanced prostate cancer, most commonly using docetaxel. It is not routinely used for low-risk localised disease. In newly diagnosed metastatic hormone-sensitive prostate cancer, docetaxel may be combined with androgen-deprivation therapy (ADT) and, in appropriate patients, an androgen-receptor pathway inhibitor as part of treatment intensification. In metastatic castration-resistant prostate cancer, docetaxel or cabazitaxel can control disease and prolong survival depending on prior therapy. Treatment choice depends on fitness, symptoms, disease volume, previous hormonal treatment and molecular features.

How chemotherapy works in prostate cancer

Taxane chemotherapy interferes with cell division and androgen-receptor trafficking. Unlike ADT, which lowers or blocks male-hormone signalling, chemotherapy directly targets rapidly dividing cancer-cell processes. The two approaches are often complementary rather than alternatives.

When docetaxel may be recommended

• Selected men with newly diagnosed metastatic hormone-sensitive disease as part of combination therapy
• Metastatic castration-resistant cancer progressing despite modern hormonal therapy
• Symptomatic or rapidly progressive metastatic disease where a taxane is appropriate

Cabazitaxel and later-line treatment

Cabazitaxel is another taxane used after docetaxel in selected metastatic castration-resistant patients. Sequencing may also include androgen-receptor inhibitors, PARP inhibitors for appropriate genomic alterations, radioligand therapy, bone-targeted agents and clinical trials.

Common side effects

• Low white-cell count and infection risk
• Fatigue
• Hair loss
• Nail changes
• Numbness/tingling in hands or feet
• Fluid retention with docetaxel
• Mouth sores, diarrhoea or appetite change

Monitoring

Blood counts and liver/kidney function are checked before cycles. PSA trends, symptoms and imaging assess response; PSA can behave differently from clinical benefit, so it is not used in isolation. Fever during chemotherapy requires urgent assessment because neutropenic infection can become serious quickly.

Docetaxel may be used early, not only after hormone therapy stops working

In metastatic hormone-sensitive prostate cancer, selected fit patients receive treatment intensification from the beginning. ADT may be combined with an androgen-receptor pathway inhibitor and, in suitable patients, docetaxel. Chemotherapy in this setting does not mean the cancer has already become “chemotherapy resistant” or that all hormonal options have failed.

Fever during chemotherapy is a same-day problem

Taxanes can suppress neutrophils. Fever, rigors or rapidly worsening illness during the vulnerable period after a cycle can represent neutropenic sepsis and needs urgent oncology assessment rather than waiting for routine blood tests or taking leftover antibiotics.

Sequence matters in castration-resistant disease

Later-line choices can include docetaxel, cabazitaxel, androgen-receptor pathway inhibitors, PARP-inhibitor strategies in selected molecular subgroups and radioligand therapy where appropriate. The best next treatment depends strongly on what the tumour has already been exposed to and how it responded.

What chemotherapy can and cannot do

In metastatic prostate cancer, chemotherapy is usually used to shrink or stabilise disease, relieve symptoms and extend survival; it is not generally presented as a curative treatment. A good response does not mean androgen-deprivation therapy can be stopped, because ADT remains the backbone of treatment in metastatic disease. The practical question is therefore not simply ‘Does chemotherapy work?’ but whether adding a taxane now offers more benefit than the other available systemic options.

When to seek earlier medical review

During chemotherapy, fever, rigors, severe breathlessness, uncontrolled vomiting/diarrhoea, confusion or rapidly worsening weakness requires prompt oncology assessment. Report progressive numbness, swelling or pain earlier, before toxicity becomes difficult to reverse.

What to bring to your consultation

• Pathology and staging scans
• PSA/testosterone trend
• Previous hormone/ARPI treatment timeline
• Recent blood counts, kidney/liver tests and medication list

Questions to ask your doctor

• Is chemotherapy being added in hormone-sensitive disease or used after castration resistance?
• What should I do if I develop fever after a cycle?
• How does prior AR-pathway treatment affect the next taxane choice?

FAQs

Related reading

• Prostate Cancer: Symptoms, Diagnosis and Treatment
• PSA Test for Prostate Cancer
• Prostate MRI Explained
• Prostate Biopsy Report Explained
• Prostate Cancer Stages Explained
• Chemotherapy and Immunotherapy for Advanced Bladder Cancer
• Urologist in Latur

References

• European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
• European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Treatment https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
• National Cancer Institute. Prostate Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq